NCT07152392View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

April 15, 2035

Conditions
Thyroid Associated Ophthalmopathies
Interventions
DRUG

IBI311

IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 500-mg glass vials as a Injection solution containing.

OTHER

Follew-up

recived follow-up every six months

Trial Locations (1)

200003

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER